Abstract：Alzheimer’s disease is the most common cause of dementia in the current elderly population． Molecular imaging plays an important role in the basic and clinical research of Alzheimer’s disease. PET can detect pathophysiological changes in Alzheimer’s disease with different radiotracers． This paper will focus on evaluating the value of 18F-FDG and amyloid PET imaging in Alzheimer’s disease, and describe in detail the role of PET imaging in the research of etiology, early diagnosis, differential diagnosis, prognosis and medical treatment of Alzheimer’s disease．
陶 霖，郑东明. PET显像技术在阿尔茨海默病诊断中的应用[J]. 中国临床医学影像杂志, 2016, 27(5): 367-369.
TAO Lin, ZHENG Dong-ming. Application of PET imaging in the diagnosis of Alzheimer’s disease. JOURNAL OF CHINA MEDICAL IMAGING, 2016, 27(5): 367-369.
[1]Caroli A1, Prestia A, Chen K, et al. Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to head comparison[J]. J Nucl Med, 2012, 53(4): 592-600.
[2]Klunk WE, Engler H, Nordberg A, et al． Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B[J]． Ann Neurol, 2004, 55(3): 306-319．
[3]Buckner RL, Snyder AZ, Shannon BJ, et al． Molecular, structural, and functional characterization of Alzheimer’s disease: Evidence for a relationship between default activity, amyloid, and memory[J]． J Neurosci, 2005, 25(34): 7709-7717．
[4]Landau SM, Harvey D, Madison CM, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI[J]. Neurobiol Aging, 2011, 32(7): 1207-1218.
[5]左传涛，刘永昌，管一晖，等. 年龄对脑葡萄糖代谢的影响[J]. 中国医学计算机成像杂志，2001，7（3）：204-206.
[6]Herholz K, Salmon E, Perani JC, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multi-center FDG PET[J]. Neuroimage, 2002, 17(1): 302-316.
[7]Ishii K, Sasaki M, Kitagaki H, et al. Reduction of cerebellar glucose metabolism in advanced Alzheimer’s disease[J]. J Nucl Med, 1997, 38(6): 925-928.
[8]Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria[J]. Lancet Neurol, 2014, 13(6): 614-629.
[9]Mega MS, Cummings JL, O’Connor SM, et al. Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease[J]. Neuropsychiatry Neuropsychol Behav Neurol, 2001, 14(1): 63-68.
[10]Pagani M, Dessi B, Morberlli S, et al. MCI patients declining and declining at mid-term follow-up: FDG-PET findings[J]. Curr Alzheimer Res, 2010, 7(4): 287-294.
[11]Chetelat G, Eustache F, Viader F, et al. FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment[J]. Neurocase, 2005, 11(1): 14-25.
[12]Mosconi L, Tsui WH, Herholz K, et al． Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias[J]． J Nucl Med, 2008, 49(3): 390－398．
[13]Del Sole A, Clerici F, Chiti A, et al. Individual cerebral metabolic deficits in Alzheimer’s disease and amnestic mild cognitive impairment: an FDG PET study[J]. Eur J Nucl Med Mol Imaging, 2008, 35(7): 1357-1366.
[14]华逢春，冯晓源，赵倩华，等. 轻度认知障碍及阿尔茨海默病脑葡萄糖代谢改变的统计参数图的PET研究[J]. Chin J Clin Neurosci，2013，21（2）：126-132.
[15]Drzezga A, Grimmer T, Riemenschneider M, et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET[J]. J Nucl Med, 2005, 46(10): 1625-1632.
[16]李祖贵，高硕，张本恕，等. AD型与非AD型变性痴呆大脑葡萄糖代谢的SPM分析[J]. 中华核医学杂志，2008，28（1）：13-16.
[17]Bonte FJ, Harris TS, Roney CA, et al. Differential diagnosis between Alzheimer’s and frontotemporal disease by the posterior cingulate sign[J]. J Nucl Med, 2004, 45(5): 771-774.
[18]Minoshima S, Foster NL, Sima AA, et al. Alzheimer’s disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation[J]. Ann Neurol, 2001, 50(3): 358-365. [19]Okamura N, Arai H, Higuchi M. [18F]FDG-PET study in dementia with Lewy bodies and Alzheimer’s disease[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2001, 25(2): 447-456.
[20]Silverman DH. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging[J]. J Nucl Med, 2004, 45(4): 594-607.
[21]Henriksen G, Yousefi BH, Drzezga A, et al. Development and evaluation of compounds for imaging of beta-amyloid plaque by means of positron emission tomography[J]. Eur J Nucl Med Mol Imaging, 2008, 35(Suppl 1): S75-S81.
[22]Cai L, Innis RB, Pike VW. Radioligand development for PET imaging of beta-amyloid(Abeta)-current status[J]. Curr Med Chem, 2007, 14(1): 19-52.
[23]Mathis CA, Bacskai BJ, Kajdasz ST, et al． A lipophilic thioavin-T derivative for positron emission tomography(PET) imaging of amyloid in brain[J]． Bioorg Med Chem Lett, 2002, 12(3): 295-298．
[24]Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B[J]. Ann Neurol, 2004, 55(3): 306-319.
[25]Devanand DP, Mikhno A, Pelton GH, et al. Pittsburgh compound B(11C-PIB)and fluorodeoxyglucose(18F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls[J]. J Geriatr Psychiatry Neurol, 2010, 23(3): 185-198.
[26]Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PiB PET study[J]. Neurology, 2009, 73(10): 754-760.
[27]Forsberg A, Engler H, Almkvist O, et al． PET imaging of amyloid deposition in patients with mild cognitive impairment[J]． Neurobiol Aging, 2008, 29(10): 1456-1465．
[28]Kadir A, Nordberg A． Target-specic PET probes for neurodegenerative disorders related to dementia[J]． J Nucl Med, 2010, 51(9): 1418-1430．
[29]Forsberg A, Engler H, Almkvist O, et al． PET imaging of amyloid deposition inpatients with mild cognitive impairment[J]． Neurobiol Aging, 2008, 29(10): 1456-1465．
[30]Engler H, Santillo AF, Wang SX, et al. In vivo amyloid imaging with PET in frontotemporal dementia[J]. Eur J Nucl Med Mol Imaging, 2008, 35(1): 100-106.
[31]王颖，高硕，蔡莉，等. 18F-FDG和11C-PIB PET联合脑显像对阿尔茨海默病及额颞痴呆的鉴别诊断价值初探[J]. 天津医药，2013，41（5）：401-403.
[32]Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease[J]. Brain, 2006, 129(11): 2856-2866.
[33]Kadir A, Almkvist O, Forsberg A, et al. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease[J]. Neurobiol Aging, 2012, 33(1): 198. e1-14.
2016, Vol. 27 
